Interestingly, gemtuzumab–ozogamicin seems to promote cell cycle progression in CML CD34+ cells and demonstrated activation of the RUNX1 pathway in an RNAseq experiment. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.